Understand how we got here — and how to move forward.


July 5, 2022

Weekly review: Fauci is experiencing Covid-19 'rebound' after taking Paxlovid

Daily Briefing

    Researchers react to Roe's overturn, what Covid-19 boosters will look like this fall, and more.

    Researchers react— Roe is overturned (Monday, June 27)

    Radio Advisory's Rachel Woods invited Advisory Board experts to share their perspective on the biggest impact that overturning Roe v. Wade will have on providers, purchasers, and life sciences companies.

    What will Covid-19 booster shots look like this fall? (Tuesday, June 28)

    On Tuesday, a panel of experts will advise FDA on whether an updated vaccine should target a version of the omicron variant—a move that would have federal regulators decide exactly which formulation to use this fall.

    The new Enhancing Oncology Model: What you need to know (Wednesday, June 29)

    CMS last week announced a new voluntary payment model that will build off the Oncology Care Model, which ends Thursday, Maya Goldman reports for Modern Healthcare. Read on for details on the model.

    Fauci is experiencing Covid-19 'rebound' after taking Paxlovid (Thursday, June 30)

    After completing a course of Paxlovid, the antiviral developed by Pfizer for treating Covid-19, Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said he's experiencing a "rebound" of symptoms, a phenomenon that sometimes happens in patients who take the drug.

    Inside the post-Roe confusion around ectopic pregnancy treatments (Friday, July 1)

    Following the Supreme Court's decision to overturn the 1973 Roe v. Wade and 1992 Planned Parenthood v. Casey decisions, health care providers around the country are asking how the ruling will impact access to treatments for potentially life-threatening conditions, like ectopic pregnancies, Catherine Pearson reports for the New York Times.

    Have a Question?


    Ask our experts a question on any topic in health care by visiting our member portal, AskAdvisory.